A novel orally available Syk/Src/Jak2 inhibitor, SKLB-850, showed potent anti-tumor activities in B cell lymphoma (BCL) models
Nannan Zhang(Lanzhou University), Shengyong Yang(Sichuan University)
Cited by 7
Related Papers
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
|Signal Transduction and Targeted Therapy|2021|1.6k
SARS-CoV-2 M <sup>pro</sup> inhibitors with antiviral activity in a transgenic mouse model
|Science|2021|449
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
|Nature Microbiology|2022|101
Generative deep learning enables the discovery of a potent and selective RIPK1 inhibitor
|Nature Communications|2022|98
PocketFlow is a data-and-knowledge-driven structure-based molecular generative model
|Nature Machine Intelligence|2024|86